China to Give Innovative Pediatric Drugmakers Market Exclusivity of Up to Two Years

China will grant up to two years of market exclusivity to manufacturers of eligible innovative pediatric drugs to boost R&D in pediatric medicines. The new policy, issued by the National Health Commission and other ministries, also introduces patent term compensations and aims to support the development of treatments for common childhood diseases and rare diseases. Regulators will assist in improving drug development efficiency and prioritize registration applications for innovative pediatric drugs. Additionally, the government will explore a national pediatric clinical trial network and support the development of commercial insurance products for children.